A detailed history of Virtus ETF Advisers LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 45,490 shares of TVTX stock, worth $885,235. This represents 0.31% of its overall portfolio holdings.

Number of Shares
45,490
Previous 45,490 -0.0%
Holding current value
$885,235
Previous $373,000 70.51%
% of portfolio
0.31%
Previous 0.19%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.26 - $8.28 $7,048 - $11,095
1,340 Added 3.04%
45,490 $373,000
Q1 2024

May 15, 2024

BUY
$7.18 - $9.82 $45,607 - $62,376
6,352 Added 16.81%
44,150 $340,000
Q4 2023

Feb 15, 2024

BUY
$5.44 - $9.5 $107,804 - $188,261
19,817 Added 110.21%
37,798 $339,000
Q3 2023

Nov 07, 2023

SELL
$7.64 - $17.25 $17,785 - $40,158
-2,328 Reduced 11.46%
17,981 $160,000
Q2 2023

Aug 14, 2023

BUY
$15.3 - $22.61 $55,615 - $82,187
3,635 Added 21.8%
20,309 $311,000
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $5,221 - $6,706
293 Added 1.79%
16,674 $374,000
Q4 2022

Feb 14, 2023

BUY
$18.47 - $26.14 $117,506 - $166,302
6,362 Added 63.5%
16,381 $344,000
Q3 2022

Nov 14, 2022

BUY
$22.91 - $28.63 $3,299 - $4,122
144 Added 1.46%
10,019 $247,000
Q2 2022

Aug 12, 2022

SELL
$20.94 - $30.01 $88,806 - $127,272
-4,241 Reduced 30.04%
9,875 $239,000
Q4 2021

Feb 14, 2022

SELL
$24.34 - $31.17 $375,493 - $480,859
-15,427 Reduced 52.22%
14,116 $438,000
Q3 2021

Nov 15, 2021

SELL
$12.98 - $25.03 $35,188 - $67,856
-2,711 Reduced 8.41%
29,543 $716,000
Q2 2021

Aug 10, 2021

BUY
$14.11 - $26.4 $117,776 - $220,360
8,347 Added 34.91%
32,254 $471,000
Q1 2021

May 17, 2021

BUY
$23.37 - $31.77 $558,706 - $759,525
23,907 New
23,907 $597,000

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $1.25B
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.